Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRB | P09619 | 5/20 | 0.52 |
| ▸ | FLT3 | P36888 | 5/20 | 0.52 |
| ▸ | FLT4 | P35916 | 4/20 | 0.52 |
| ▸ | KDR | P35968 | 8/20 | 0.48 |
| ▸ | AURKA | O14965 | 8/20 | 0.48 |
| ▸ | AURKB | Q96GD4 | 7/20 | 0.48 |
| ▸ | EGFR | P00533 | 5/20 | 0.48 |
| ▸ | KIT | P10721 | 4/20 | 0.48 |
| ▸ | PDGFRA | P16234 | 3/20 | 0.48 |
| ▸ | FLT1 | P17948 | 2/20 | 0.48 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.48 |
| ▸ | LCK | P06239 | 2/20 | 0.48 |
| ▸ | LYN | P07948 | 2/20 | 0.48 |
| ▸ | RET | P07949 | 2/20 | 0.48 |
| ▸ | HCK | P08631 | 2/20 | 0.48 |
| ▸ | CSNK2A2 | P19784 | 2/20 | 0.48 |
| ▸ | MST1R | Q04912 | 2/20 | 0.48 |
| ▸ | MAP2K5 | Q13163 | 2/20 | 0.48 |
| ▸ | AURKC | Q9UQB9 | 2/20 | 0.48 |
| ▸ | MAP4K5 | Q9Y4K4 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5042816 | 0.89 | PDGFRB (0.51) | PDGFRBFLT3FLT4KDRAURKA | |
| SCHEMBL5042725 | 0.87 | PDGFRB (0.48) | PDGFRBFLT3FLT4KDRAURKA | |
| SCHEMBL2049622 | 0.87 | PDGFRB (0.49) | PDGFRBFLT3FLT4KDRAURKA | |
| SCHEMBL3424451 | 0.86 | AURKA (0.66) | PDGFRBFLT3FLT4KDRAURKA | |
| SCHEMBL2053145 | 0.85 | FLT3 (0.69) | PDGFRBFLT3FLT4KDRAURKA | |
| SCHEMBL6026358 | 0.83 | PDGFRB (0.53) | PDGFRBFLT3FLT4KDRAURKA | |
| Hydrochloric Acid SCHEMBL5043171 | 0.83 | KDR (0.52) | PDGFRBFLT3FLT4KDRAURKA | |
| SCHEMBL27859112 | 0.81 | KDR (0.43) | PDGFRBFLT3FLT4KDRAURKA | |
| SCHEMBL2052923 | 0.78 | PDGFRB (0.65) | PDGFRBFLT3FLT4KDRAURKA | |
| SCHEMBL2049861 | 0.76 | AURKA (0.67) | PDGFRBFLT3FLT4KDRAURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1809557-B | Compound | ASTRAZENECA AB | 2012-07-04 | — | — | CN | claimed |
| JP-4709139-B2 | — | — | 2011-06-22 | — | — | JP | claimed |
| US-7691867-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2010-04-06 | — | — | US | claimed |
| EP-1613619-B1 | QUINAZOLINE DERIVATIVES FOR TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2008-03-26 | — | — | EP | claimed |
| US-20060270692-A1 | Chemical compounds | ASTRAZENECA AB (SE) | 2006-11-30 | — | — | US | claimed |
| JP-2006523660-A | — | — | 2006-10-19 | — | — | JP | claimed |
| EP-1613619-A1 | QUINAZOLINE DERIVATIVES FOR TREATMENT OF CANCER | AstraZeneca AB (SE) | 2006-01-11 | — | — | EP | claimed |
| WO-2004094410-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2004-11-04 | — | — | WO | claimed |
| CN-1809557-B | Compound | ASTRAZENECA AB | 2012-07-04 | — | — | CN | disclosed |
| US-7691867-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2010-04-06 | — | — | US | disclosed |
| EP-1613619-B1 | QUINAZOLINE DERIVATIVES FOR TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2008-03-26 | — | — | EP | disclosed |
| US-20060270692-A1 | Chemical compounds | ASTRAZENECA AB (SE) | 2006-11-30 | — | — | US | disclosed |
| EP-1613619-A1 | QUINAZOLINE DERIVATIVES FOR TREATMENT OF CANCER | AstraZeneca AB (SE) | 2006-01-11 | — | — | EP | disclosed |
| WO-2004094410-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2004-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060270692-A1 | Chemical compounds | CCNI, MKI67, TP53 | PDGFRB 1544/4885FLT3 703/4885FLT4 2898/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.